Get started
Author

Sofiya Kokhanovska

Observed name: S. Kokhanovska
ORCID: 0000-0001-8682-2037
Observed ORCID: 0000-0001-8682-2037
OpenAlex ID: A5008295994
Phytochemicals Rosmarinic Acid, Ampelopsin, and Amorfrutin-A Can Modulate Age-Related Phenotype of Serially Passaged Human Skin Fibroblasts in vitro
2019 · Lakshman Sodagam, Anna Lewinska, et al. · Frontiers in Genetics · 29
PDF
A PDE10A inhibitor CPL500036 is a novel agent modulating striatal function devoid of most neuroleptic side-effects
2022 · Mikolaj Matloka, Sylwia Janowska, et al. · Frontiers in Pharmacology · 9
PDF
CPL500036 – a novel inhibitor of phosphodiesterase 10A – attenuates the development of L-DOPA-induced dyskinesias in 6-OHDA lesioned rats
2022 · M. Matłoka, T. Lenda, et al. · Neuroscience Applied · 1
PDF
P.0078 Inflammatory cytokine plasma levels correlation with MADRS score in patients with treatment-resistant major depression after dry-powder inhaled esketamine administration
2021 · M. Matłoka, A. Gajos-Draus, et al. · European Neuropsychopharmacology · 1
P.105 The study of molecular changes induced by CPL500-036, a potential novel anti-dyskinetic drug, in 6-OHDA rat model of Parkinson's disease
2020 · A. Gajos-Draus, K. Mulewski, et al. · European Neuropsychopharmacology · 1
Uncovering mechanistic differences among PDE10A inhibitors: a multilevel molecular, functional and behavioral comparison underlying the clinical efficacy of CPL’36
2026 · J. Krzemień, S. Kokhanovska, et al. · Neuroscience Applied
A novel functional platform for the discovery of trace amine-associated receptor 1 agonists with dual gαs and gαq activity
2024 · S. Kokhanovska, K. Skowrońska, et al. · Neuroscience Applied
Repeated, 4-week dosing of CPL500036, a novel phosphodiesterase 10A inhibitor, does not induce tolerance to its antipsychotic-like action
2023 · J. Krzemień, A. Nikiforuk, et al. · Neuroscience Applied
Works count: 8
Citation count: 41
H-index: 2
I10-index: 1
Year
Topic
Type